Survival and clonal evolution
death, neutropenia, pulmonary infection
NEUTROPENIA, PULMONARY INFECTION
Three patients (3.9%) died in the EPAG+tacrolimus group during follow-up, and the causes of death included pulmonary infection related to neutropenia for two patients and unknown reasons for one patient. None of the three patients responded, and they died at a median of 5 (1–6) months after discontinuing treatment. On the other hand, one NR patient (2.6%) in the EPAG monotherapy group died from unknown reasons at 3 months after discontinuing EPAG. No significant difference was found in the cumulative overall survival curve between the groups (